Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Capricor expands Cedars-Sinai agreements
February 2018
SHARING OPTIONS:

LOS ANGELES—Mid-January saw Capricor Therapeutics announce the addition of seven new patent applications to its exclusive license agreements with Cedars-Sinai Medical Center for technologies related to cardiosphere-derived cells (CDCs) and CDC-derived extracellular vesicles. The agreements give Capricor exclusive worldwide rights to commercially develop and market CDCs and CDC-derived exosomes, which includes two of Capricor’s lead therapies, CAP-1002 and CAP-2003. These applications widen the scope of the agreements to allow Capricor to develop new therapeutic indications for its cellular and exosome therapies in Duchenne muscular dystrophy, ventricular tachyarrhythmia, cancer and age-related disorders.
 
“Obtaining the rights to these additional patent applications will expand and potentially strengthen Capricor’s intellectual property portfolio,” said Dr. Linda Marbán, Capricor’s president and CEO. “Capricor is moving forward with a clinical trial this year for CAP-1002 as an intravenous therapy in Duchenne muscular dystrophy. Pending regulatory approval, we also plan to launch a clinical trial of CAP-2003 in hypoplastic left heart syndrome.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.